Innovations in Healthcare: Stryker's FDA Approval, OneMedNet's Funding, and CHMP's Nod to RYBREVANT

Recent Advances in Medical Technologies and Therapies: Stryker's innovative spine surgery technology receives FDA approval, OneMedNet raises $4.6 million in private funding, and the CHMP endorses RYBREVANT® (amivantamab) combined with chemotherapy for advanced EGFR-mutated NSCLC post-therapy failure.